Wonder if this is net positive or net negative for ARRY and ARRY-520. Negative in the sense that it's another competitor on the market ahead of 520. Positive in the sense that it provides a roadmap for potential approval for 520 (if the data ends up supporting that; early days still for 520). Positive in the sense that approval for CELG here could make ONXX even more open to doing combo trials of kyprolis+520 (these are ongoing now but it's unclear that ONXX has clear interest as I believe these are ISTs). I.e., clear good news for one competitor in the space may put pressure on others to attempt to further differentiate their drug.
Market Data 
Markets 
AI
